170 related articles for article (PubMed ID: 23061737)
1. Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.
Willemen MJ; Mantel-Teeuwisse AK; Buggy Y; Layton D; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2012 Dec; 35(12):1147-58. PubMed ID: 23061737
[TBL] [Abstract][Full Text] [Related]
2. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.
Buggy Y; Cornelius V; Wilton L; Shakir SA
Drug Saf; 2011 Jun; 34(6):501-9. PubMed ID: 21585222
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.
Chavez-Tapia NC; Tellez-Avila FI; Bedogni G; Crocè LS; Masutti F; Tiribelli C
BMC Gastroenterol; 2009 Oct; 9():75. PubMed ID: 19818116
[TBL] [Abstract][Full Text] [Related]
5. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topol EJ; Bousser MG; Fox KA; Creager MA; Despres JP; Easton JD; Hamm CW; Montalescot G; Steg PG; Pearson TA; Cohen E; Gaudin C; Job B; Murphy JH; Bhatt DL;
Lancet; 2010 Aug; 376(9740):517-23. PubMed ID: 20709233
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
7. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
8. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
9. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
Kasliwal R; Wilton LV; Shakir SA
Drug Saf; 2009; 32(6):499-507. PubMed ID: 19459717
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rimonabant in obese patients with binge eating disorder.
Pataky Z; Gasteyger C; Ziegler O; Rissanen A; Hanotin C; Golay A
Exp Clin Endocrinol Diabetes; 2013 Jan; 121(1):20-6. PubMed ID: 23147209
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
12. Psychosis following anti-obesity treatment with rimonabant.
Ugur T; Bartels M; Kis B; Scherbaum N
Obes Facts; 2008; 1(2):103-5. PubMed ID: 20054169
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
[TBL] [Abstract][Full Text] [Related]
14. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
[TBL] [Abstract][Full Text] [Related]
15. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.
Motaghedi R; Lipman EG; Hogg JE; Christos PJ; Vogiatzi MG; Angulo MA
Eur J Med Genet; 2011; 54(1):14-8. PubMed ID: 20965292
[TBL] [Abstract][Full Text] [Related]
17. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
Patel PN; Pathak R
Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid type 1 receptor antagonists for smoking cessation.
Cahill K; Ussher MH
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
[TBL] [Abstract][Full Text] [Related]
20. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
